

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION ON THE GROUP'S PRODUCT AMOXICILLIN CLAVULANATE POTASSIUM TABLETS

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the Amoxicillin Clavulanate Potassium Tablets (specification: 0.375g) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, with the approval of China National Medical Products Administration, passed the consistency evaluation of quality and efficacy for generic drugs ("Consistency Evaluation").

Amoxicillin clavulanate potassium tablet is a broad-spectrum penicillin antibiotic. It is clinically applicable to the treatment of infections caused by β -lactamase producing bacteria, such as respiratory tract infection, skin and soft tissue infection, urinary system infection and other bacterial infections. It is a safe and reliable antibacterial drug widely used in clinical basic medication with exact efficacy. At present, the product has been listed in the National Essential Drug List (2018 version) and Category A in the National Medical Insurance Drug List (2022 version).

This approval will further enhance the brand value of the Group's products as well as the market competitiveness. In the future, the Company will continue to devote itself to the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater values for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 24 April 2024

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.